TSE:RBM Response Biomedical (RBM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Response Biomedical Stock (TSE:RBM) Get Response Biomedical alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume1,707 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Response Biomedical Corp. (Response) offers diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. The Company operates through the research, development, commercialization and distribution of diagnostic technologies segment. The Company develops, manufactures and sells its RAMP system for the global medical point of care market, including cardiovascular testing, infectious disease testing market and the on-site environmental testing market, including biodefense and vector environmental testing. In the United States, its RAMP 200 Reader is limited to central-lab use with the cardiovascular tests. POC, on-site diagnostic tests (or assays) are non-laboratory-based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. The Company's RAMP system is a platform technology that combines a fluorescence detection system with lateral flow immunoassays. Read More Receive RBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Response Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RBM Stock News HeadlinesBisk Announces Contract Renewal with the USF Health Morsani College of MedicineAugust 25, 2022 | apnews.comAPOINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business HighlightsAugust 12, 2022 | apnews.comADo NOT Buy the Next $2 Trillion IPO Before Reading ThisAnthropic is reportedly preparing to file its IPO prospectus shortly after Labor Day, with a potential valuation as high as 2 trillion dollars. Before the headlines and hype hit, Michael Robinson says there is something investors should understand first, what he calls the Big IPO Lie. He has uncovered a different way to look at Anthropic's move ahead of its public debut.September 4 at 1:00 AM | Weiss Ratings (Ad)Global Genomic Cancer Panel and Profiling Market Research Report 2022July 28, 2022 | finance.yahoo.comMolecular Diagnostics for Cancer Market Report 2022: Featuring Key Players Abbott Diagnostics, Bristol-Myers Squibb, Janssen Diagnostics & OthersJuly 9, 2022 | finance.yahoo.comEmergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for EbolaJuly 7, 2022 | finance.yahoo.comEmergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine CandidateJune 24, 2022 | yahoo.comDelveInsight Business Research, LLP: Age-related Macular Degeneration Market to Progress at a CAGR of 3.4% by 2032 | DelveInsightJune 15, 2022 | finanznachrichten.deSee More Headlines RBM Stock Analysis - Frequently Asked Questions How do I buy shares of Response Biomedical? Shares of RBM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Response Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Response Biomedical investors own include TUI (TUI), Marston's (MARS), Hornby (HRN) and Aston Martin Lagonda Global (AML). Industry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolTSE:RBM CIKN/A Webwww.responsebio.com Phone+1-604-4566010FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (TSE:RBM) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredMan Who Called SpaceX Rise Says Elon’s NEW Project is Even BiggerJames Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...Paradigm Press | SponsoredHalf the market is standing on a trapdoorNearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...Behind the Markets | SponsoredA New Approach to Retirement Income That Needs Less CapitalThe secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Response Biomedical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Response Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.